Smart. Sharp. Funny. Fearless.
Monday, July 16, 2018

Trump Talked ‘Witch Hunt’ But Knew Indictments Were Imminent

Reprinted with permission from Shareblue.

 

Despite being fully briefed that 12 members of Russia’s military intelligence agency would soon be indicted for hacking Democratic emails during the 2016 campaign, Trump still denounced U.S. law enforcement’s pursuit of the case as a “witch hunt” while he was overseas this week.

“I think I would have a very good relationship with Putin if we spend time together. After watching the rigged witch-hunt yesterday, I think it really hurts our country and our relationship with Russia,” he said Friday during his joint press conference with British Prime Minister Theresa May.

He was referring to Thursday’s circus-like hearing of the House Judiciary and Oversight committees, where Republicans once against tried — and failed — to discredit special counsel Robert Mueller’s investigation.…

Read More

Ocasio-Cortez Ran High-Tech Crusade Against Crowley’s Obsolete Campaign

There are many reasons why working-class champion Alexandria Ocasio-Cortez won the biggest political upset of 2018 so far—a first-time candidate badly beating Rep. Joseph Crowley (D-NY), who was one of the Democratic Party’s top leaders in Washington, a prodigious fundraiser, and boss of the Queens County Democratic Party.

But beyond her deeply resonant pledges to work on behalf of her district’s overlooked working-class voters, Ocasio-Cortez’s victory in this week’s New York congressional primaries would not have been possible without her sophisticated use of online tools to organize, communicate, motivate and turn out voters.

Crowley’s campaign, as one insider told the New York Times, was from an earlier pre-internet era, one dominated by big dollar fundraising, and mass marketing via mailings of campaign flyers, and TV and radio ads.

Read More

FDA Is Now Rushing Risky Drugs To Market

Reprinted with permission from ProPublica.

 

FDA Repays Industry by Rushing Risky Drugs to Market

Nuplazid, a drug for hallucinations and delusions associated with Parkinson’s disease, failed two clinical trials. In a third trial, under a revised standard for measuring its effect, it showed minimal benefit. Overall, more patients died or had serious side effects on Nuplazid than after receiving no treatment.

Patients on Uloric, a gout drug, suffered more heart attacks, strokes and heart failure in two out of three trials than did their counterparts on standard or no medication.

Nevertheless, the U.S. Food and Drug Administration approved both of these drugs — with a deadly aftermath.



Read More